Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson’s disease: review and current status

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.8, Iss.4, 1999-04, pp. : 453-462

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production

By Nissinen E. Kaheinen P. Penttila K.E. Kaivola J. Linden I.-B.

European Journal of Pharmacology, Vol. 340, Iss. 2, 1997-12 ,pp. : 287-294

Elsevier

Access to resources Recommend Favorite

Catechol-O-Methyltransferase and Alzheimer's Disease: A Review of Biological and Genetic Findings

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 3, 2012-05 ,pp. : 299-305

Bentham Science Publishers

Access to resources Recommend Favorite

Entacapone in the management of Parkinson’s disease

By Waters Cheryl Henchcliffe Claire

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. : 957-963

Informa Healthcare

Access to resources Recommend Favorite

Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson’s Disease and L-DOPA Treatment

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 3, 2012-05 ,pp. : 251-263

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of Catechol-O-Methyltransferase

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 3, 2012-05 ,pp. : 324-332

Bentham Science Publishers

Access to resources Recommend Favorite